Humacyte Inc [HUMA] stock is trading at $2.24, up 18.52%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The HUMA shares have gain 88.24% over the last week, with a monthly amount glided 44.52%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, H.C. Wainwright reaffirmed its Buy rating on December 20, 2024, and elevated its price target to $15. On December 11, 2023, H.C. Wainwright initiated with a Buy rating and assigned a price target of $6 on the stock. Piper Sandler upgraded its rating to a Neutral and increased its price target to $3.50 on August 14, 2023. Cantor Fitzgerald initiated its recommendation with a Overweight and recommended $6 as its price target on June 22, 2023. Piper Sandler downgraded its rating to Underweight for this stock on May 16, 2022, and downed its price target to $4. In a note dated October 29, 2021, Cowen initiated an Outperform rating and provided a target price of $17 on this stock.
Humacyte Inc [HUMA] stock has fluctuated between $1.15 and $9.97 over the past year. Currently, Wall Street analysts expect the stock to reach $7 within the next 12 months. Humacyte Inc [NASDAQ: HUMA] shares were valued at $2.24 at the most recent close of the market. An investor can expect a potential return of 212.5% based on the average HUMA price forecast.
Analyzing the HUMA fundamentals
Gross Profit Margin for this corporation currently stands at 0.23% with Operating Profit Margin at -14.33%, Pretax Profit Margin comes in at -10.03%, and Net Profit Margin reading is -10.03%. To continue investigating profitability, this company’s Return on Assets is posted at -0.48, Equity is 2.86 and Total Capital is -0.78. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.44.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.93 points at the first support level, and at 1.63 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.40, and for the 2nd resistance point, it is at 2.57.
Ratios To Look Out For
For context, Humacyte Inc’s Current Ratio is 3.68. Also, the Quick Ratio is 3.28, while the Cash Ratio stands at 3.14. Considering the valuation of this stock, the price to sales ratio is 668.21, the price to book ratio is 9.64.
Transactions by insiders
Recent insider trading involved Scheessele William John, Chief Commercial Officer, that happened on Apr 14 ’25 when 6493.0 shares were purchased. CFO and Chief Corp. Deve. Off., Sander Dale A. completed a deal on Apr 10 ’25 to buy 20000.0 shares. Meanwhile, Chief Medical Officer Parikh Shamik J bought 7500.0 shares on Apr 10 ’25.
